CYLC2

Across TCGA pan-cancer cohorts, CYLC2 RNA is linked to patient survival in 12 of 34 cancer types, making it the most broadly survival-associated CYLC2 data layer compared with 9 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CYLC2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CYLC2 expression acts as an unfavorable survival marker, although some lineages such as SCLC show a favorable association.

LUAD, COAD, and ACC are the cancer types where CYLC2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	II,III,IV	0.372	0.719	<.001	135	view →
COAD	OS	Tertile	III,IV	0.242	0.704	<.001	126	view →
ACC	OS	Tertile	All	0.156	0.705	.005	60	view →
OV	OS	Tertile	II,III,IV	0.737	0.851	.002	54	view →
KIRC	OS	Tertile	All	0.520	0.678	<.001	48	view →
HNSC	DFS	Tertile	II,III,IV	0.583	0.714	.010	30	view →
THCA	DFS	Tertile	All	0.748	0.933	.002	24	view →
KICH	OS	Tertile	III,IV	0.178	0.847	<.001	21	view →
UVM	OS	Tertile	All	0.292	0.674	.035	18	view →
CESC	OS	Tertile	IV	0.254	0.627	.040	18	view →
SCLC	DFS	Tertile	II,III,IV	0.849	0.534	.017	15	view →
ESCA	DFS	Tertile	All	0.461	0.870	.022	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

CYLC2–LUAD (OS)

Open the LUAD breakdown →